The stock of Portage Biotech Inc (NASDAQ: PRTG) has increased by 18.96 when compared to last closing price of 5.38.Despite this, the company has seen a gain of 11.50% in its stock price over the last five trading days. globenewswire.com reported 2025-06-25 that DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
Is It Worth Investing in Portage Biotech Inc (NASDAQ: PRTG) Right Now?
The 36-month beta value for PRTG is at 0.63. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PRTG is 0.28M, and currently, shorts hold a 5.80% of that float. The average trading volume for PRTG on June 25, 2025 was 1.35M shares.
PRTG’s Market Performance
PRTG’s stock has seen a 11.50% increase for the week, with a -18.88% drop in the past month and a 57.25% gain in the past quarter. The volatility ratio for the week is 3.15%, and the volatility levels for the past 30 days are at 5.25% for Portage Biotech Inc The simple moving average for the past 20 days is -8.46% for PRTG’s stock, with a 9.40% simple moving average for the past 200 days.
Analysts’ Opinion of PRTG
Many brokerage firms have already submitted their reports for PRTG stocks, with Oppenheimer repeating the rating for PRTG by listing it as a “Outperform.” The predicted price for PRTG in the upcoming period, according to Oppenheimer is $26 based on the research report published on July 18, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PRTG reach a price target of $32. The rating they have provided for PRTG stocks is “Buy” according to the report published on March 07th, 2022.
Oppenheimer gave a rating of “Outperform” to PRTG, setting the target price at $30 in the report published on September 21st of the previous year.
PRTG Trading at -20.65% from the 50-Day Moving Average
After a stumble in the market that brought PRTG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.19% of loss for the given period.
Stock Fundamentals for PRTG
The total capital return value is set at -6.41. Equity return is now at value -194.84, with -136.43 for asset returns.
Based on Portage Biotech Inc (PRTG), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -349.79. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -733.94.
Currently, EBITDA for the company is -18.2 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.08.
Conclusion
In conclusion, Portage Biotech Inc (PRTG) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
